Document Type
Article
Publication Date
1-29-2021
Keywords
JGM
JAX Source
Commun Biol 2021 Jan 29; 4(1):129.
Volume
4
Issue
1
First Page
129
Last Page
129
ISSN
2399-3642
PMID
33514825
DOI
https://doi.org/10.1038/s42003-021-01649-6
Grant
AI121920; AI142733; NS105539
Abstract
Development of antibody protection during SARS-CoV-2 infection is a pressing question for public health and for vaccine development. We developed highly sensitive SARS-CoV-2-specific antibody and neutralization assays. SARS-CoV-2 Spike protein or Nucleocapsid protein specific IgG antibodies at titers more than 1:100,000 were detectable in all PCR+ subjects (n = 115) and were absent in the negative controls. Other isotype antibodies (IgA, IgG1-4) were also detected. SARS-CoV-2 neutralization was determined in COVID-19 and convalescent plasma at up to 10,000-fold dilution, using Spike protein pseudotyped lentiviruses, which were also blocked by neutralizing antibodies (NAbs). Hospitalized patients had up to 3000-fold higher antibody and neutralization titers compared to outpatients or convalescent plasma donors. Interestingly, some COVID-19 patients also possessed NAbs against SARS-CoV Spike protein pseudovirus. Together these results demonstrate the high specificity and sensitivity of our assays, which may impact understanding the quality or duration of the antibody response during COVID-19 and in determining the effectiveness of potential vaccines.
Recommended Citation
Dogan M,
Kozhaya L,
Placek L,
Gunter C,
Yigit M,
Hardy R,
Plassmeyer M,
Coatney P,
Lillard K,
Bukhari Z,
Kleinberg M,
Hayes C,
Arditi M,
Klapper E,
Merin N,
Liang B,
Gupta R,
Alpan O,
Unutmaz D.
SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus. Commun Biol 2021 Jan 29; 4(1):129.
Comments
This article is licensed under a Creative Commons Attribution 4.0 International License.